Pharmtech
Developing and bringing a new drug to market is a long, expensive, and uncertain process. It’s even more complicated when it comes to complex products such as modified-release products and biologics. Bio/pharma companies can adopt proven strategies to increase the success of a product launch: cross-functional team collaboration, risk understanding and mitigation, a dedicated team, and the right project management tools. In this webcast, experts will share insights gained from decades of experience launching new products and discuss case studies demonstrating how to reliably bring products to market quickly without sacrificing compliance.
Watch Now
ICON
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting some 40,000 individuals in Europe at any time, causing 10,000 deaths each year. As with other age-related neurodegenerative diseases, the drug development field is littered with inconclusive or negative trials. Modifying Immune Response and Outcomes in ALS (MIROCALS) is an international European Union H2020-funded trial of low-dose interleukin-2 in motor neuron disease (MND)/ALS. It aims to break this impasse in the development of disease-modifying agents through novel trial design, incident (early post-diagnosis) recruitment, integration of biomarkers/transcriptomics and cohort stratification. Join this webinar to hear about an overview of the study in addition to a discussion of the challenges both anticipated and unanticipated in recruiting participants recently diagnosed with a rare, rapidly disabling and ultimately life-limiting condition.
Watch Now
At Natoli Scientific, we’re in the lab every day compiling thorough USP Tablet Compression Characterization data to help you identify and solve compaction problems and provide solutions.
Watch Now
Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.
Watch Now